 |
80 Diseases |  |
2 Trials |
|
2 Trials |  |
151 News |  |
| «123 |
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) - Feb 21, 2013
P1, N=12, Terminated, Sponsor: Angela Taber MD
N=25 --> 12
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change, Metastases: Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) (clinicaltrials.gov) - Jan 24, 2013
P2, N=50, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=25 --> 12 N=67 --> 50
- || Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Biomarker, Enrollment change: The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) (clinicaltrials.gov) - Jan 22, 2013
P1, N=63, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=67 --> 50 N=48 --> 63
- ||||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (clinicaltrials.gov) - Jan 16, 2013
P3, N=711, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=48 --> 63 Active, not recruiting --> Completed
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Biomarker, Trial completion: The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) (clinicaltrials.gov) - Dec 27, 2012
P1, N=63, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial termination: A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) (clinicaltrials.gov) - Oct 18, 2012
P2, N=80, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Completed --> Terminated
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) (clinicaltrials.gov) - Aug 8, 2012
P2, N=130, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated Active, not recruiting --> Completed
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial withdrawal, Combination therapy, Metastases: Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 10, 2012
P1, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change, Combination therapy, Metastases: Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 10, 2012
P1, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center at San Antonio
Not yet recruiting --> Withdrawn N=70 --> 0
- ||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
New P2 trial: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - May 22, 2012
P2, N=84, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change: A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) (clinicaltrials.gov) - May 17, 2012
P2, N=80, Terminated, Sponsor: Merck Sharp & Dohme Corp.
N=70 --> 0 N=150 --> 80
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change: Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) (clinicaltrials.gov) - May 3, 2012
P1, N=15, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=150 --> 80 N=12 --> 15
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) (clinicaltrials.gov) - Apr 23, 2012
P1, N=15, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=12 --> 15 Active, not recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) (clinicaltrials.gov) - Mar 26, 2012
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
New P1 trial, Monotherapy, Metastases: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (clinicaltrials.gov) - Sep 7, 2011
P1, N=21, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
New P1 trial, Metastases: A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) (clinicaltrials.gov) - Sep 7, 2011
P1, N=21, Completed, Sponsor: Merck